MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its price target increased by Wedbush from $61.00 to $86.00 in a research report report published on Monday, Marketbeat Ratings reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q3 2023 earnings at ($0.17) EPS, Q4 2023 earnings at ($0.17) […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its price objective increased by HC Wainwright from $37.00 to $75.00 in a research note released on Monday morning, FlyOnTheWall reports. MLTX has been the subject of a number of other research reports. Guggenheim lifted their price target on shares of MoonLake Immunotherapeutics from $51.00 to $65.00 in […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $58.42 and last traded at $54.27, with a volume of 1524559 shares changing hands. The stock had previously closed at $50.07. Analyst Upgrades and Downgrades Several equities research analysts […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its target price increased by Cantor Fitzgerald from $29.00 to $65.00 in a research note released on Monday morning, FlyOnTheWall reports. Several other research firms have also weighed in on MLTX. 22nd Century Group restated a reiterates rating on shares of MoonLake Immunotherapeutics in a research note on […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) major shareholder Bihua Chen purchased 450,000 shares of the business’s stock in a transaction dated Monday, June 26th. The stock was bought at an average price of $45.63 per share, for a total transaction of $20,533,500.00. Following the completion of the acquisition, the insider now owns 4,127,100 shares of […]